Successful combination therapy with corticosteroids, biweekly intravenous pulse cyclophosphamide and cyclosporin A for acute interstitial pneumonia in patients with dermatomyositis: Report of three cases

Japanese Journal of Clinical Immunology

Volumn 36, Issue 2, 2013, Pages 122-128

  Suzuki, Akitake ^a   Shoji, Norikazu ^a   Kikuchi, Eigo ^a   Uekubo, Kazuaki ^a   Aoki, Naoko ^a   Sonoda, Yui ^a   Torigai, Hideyuki ^a   Yamashita, Hiroyuki ^b   Fujita, Kentaro ^b   Okai, Takahiro ^a  

^a Center for Rheumatology and Joint Surgery Kawakita General Hospital   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Acute interstitial pneumonia; Biweekly intravenous pulse cyclophosphamide; Cyclosporine A; Dermatomyositis; Diffuse alveolar damage

Indexed keywords

EID: 84940299942     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.36.122     Document Type: Article

References (30)

1. Mills ES. and Mathews WH: Interstitial pneu-monitis in dermatomyositis. Journal of the American Medical Association. 160: 1467-1470, 1956.
2. Hunninghake GW. and Fauci AS: Pulmonary involvement in the collagen vascular diseases. The American review of respiratory disease 119: 471-503, 1979.
3. Selva-O'Callaghan A. et al: Polymyositis/der-matomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 14: 534-542, 2005.
4. Tazelaar HD., et al: Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. The American review of respiratory disease 141: 727-733, 1990.
5. Won Huh J., et al: Two distinct clinical types of interstitial lung disease associated with poly-myositis-dermatomyositis. Respir Med 101: 1761-1769, 2007.
6. Mukae H., et al: Clinical diŠerences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136: 1341-1347, 2009.
7. Sontheimer RD: Dermatomyositis: an overview of recent progress with emphasis on der-matologic aspects. Dermatologic clinics 20: 387-408, 2002.
8. Yousem SA., et al: The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Modern pathology 23: 874-880, 2010.
9. Connors GR., et al: Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138: 1464-1474, 2010.
10. Ando M., et al: Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 29: 443-445, 2010.
11. Kameda H., et al: Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32: 1719-1726, 2005.
12. Matsuki Y., et al: DiŠuse alveolar damage in patients with dermatomyositis: a six-case series. Mod Rheumatol 22: 243-248, 2012.
13. Tanimoto K., et al: Classification criteria for polymyositis and dermatomyositis. J Rheumatol 22: 668-674, 1995.
14. Bohan A and Peter JB: Polymyositis and dermatomyositis (second of two parts): N Engl J Med 292: 403-407, 1975.
15. Yamasaki Y., et al: Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol 38: 1636-1643, 2011.
16. Fudman EJ. and Schnitzer TJ: Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med 80: 329-332, 1986.
17. Ito M., et al: Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18: 462-467, 1999.
18. Kashiwabara K. and Ota K: Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phos-phokinase, severe muscle symptoms and positive anti-Jo-1 antibody. Intern Med 41: 584-588, 2002.
19. Bouros D., et al: Acute interstitial pneumonia. Eur Respir J 15: 412-418, 2000.
20. Akira M: Computed tomography and pathologic findings in fulminant forms of idiopathic interstitial pneumonia. J Thorac Imaging 14: 76-84, 1999.
21. Ichikado K., et al: Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. Am J Roentgenol 168: 333-338, 1997.
22. Miyazaki E., et al: Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol 26: 436-439, 2007.
23. Tanaka F., et al: Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 39: 428-430, 2000.
24. Turk JL., et al: The effect of cyclophosphamide on immunological control mechanisms. International journal of tissue reactions 6: 205-211, 1984.
25. Stone JH., et al: Rituximab versus cyclophosphamide for ANCA-associated vasculi-tis. NEngl JMed 363: 221-232, 2010.
26. El-Zammar O., et al: Proliferative activity in fibrosing lung diseases: a comparative study of Ki-67 immunoreactivity in diffuse alveolar damage, bronchiolitis obliterans-organizing pneumonia, and usual interstitial pneumonia. Hum Pathol 40: 1182-1188, 2009.
27. Tsuda K., et al: Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. PloS one 7: e31465, 2012.
28. Houssiau FA., et al: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61-64, 2010.
29. Houssiau FA., et al: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Ann Rheum Dis 46: 2121-2131, 2002.
30. Tesar V and Hruskova Z: Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol 7: 96-109, 2011.